Pfizer Inc. (NYSE:PFE) Shares Purchased by Wolff Wiese Magana LLC

Wolff Wiese Magana LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 108.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,342 shares of the biopharmaceutical company’s stock after buying an additional 1,741 shares during the period. Wolff Wiese Magana LLC’s holdings in Pfizer were worth $97,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Olistico Wealth LLC acquired a new stake in Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $31,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday, October 3rd. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $34.10.

Pfizer Price Performance

Shares of NYSE PFE opened at $29.66 on Thursday. The business has a 50 day simple moving average of $29.04 and a 200-day simple moving average of $28.42. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $33.19. The company has a market capitalization of $168.07 billion, a price-to-earnings ratio of -494.33, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the company earned $0.67 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.66%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.